Cargando…

Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations

OBJECTIVES: Pertussis toxin (PT) is a component of all acellular pertussis vaccines. PT must be detoxified to be included in acellular vaccines, which results in conformational changes in the functional epitopes of PTs. Therefore, induced epitope‐specific antibodies to PT may vary after vaccinations...

Descripción completa

Detalles Bibliográficos
Autores principales: Knuutila, Aapo, Dalby, Tine, Barkoff, Alex‐Mikael, Jørgensen, Charlotte Sværke, Fuursted, Kurt, Mertsola, Jussi, Markey, Kevin, He, Qiushui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396262/
https://www.ncbi.nlm.nih.gov/pubmed/32765879
http://dx.doi.org/10.1002/cti2.1161
_version_ 1783565553044029440
author Knuutila, Aapo
Dalby, Tine
Barkoff, Alex‐Mikael
Jørgensen, Charlotte Sværke
Fuursted, Kurt
Mertsola, Jussi
Markey, Kevin
He, Qiushui
author_facet Knuutila, Aapo
Dalby, Tine
Barkoff, Alex‐Mikael
Jørgensen, Charlotte Sværke
Fuursted, Kurt
Mertsola, Jussi
Markey, Kevin
He, Qiushui
author_sort Knuutila, Aapo
collection PubMed
description OBJECTIVES: Pertussis toxin (PT) is a component of all acellular pertussis vaccines. PT must be detoxified to be included in acellular vaccines, which results in conformational changes in the functional epitopes of PTs. Therefore, induced epitope‐specific antibodies to PT may vary after vaccinations or natural infections, and this information could reveal biomarkers implicated for protection and successful immunisation. METHODS: Pertussis toxin epitope‐specific antibodies in sera from 152 vaccinated children and 72 serologically confirmed patients were tested with a blocking ELISA, based on monoclonal antibodies that target protective PT epitopes. RESULTS: All study groups induced considerable antibody titres to subunit 1 (S1). Of interest, S3 7E10‐specific antibodies were present in patients, but not after vaccinations (P < 0.001). The impact of glutaraldehyde treatment of PT was visible on epitope 1D7 (S1), whereas epitopes 1B7 (S1) and 10D (S1) were more preserved. Antibodies to these epitopes were higher after three primary vaccine doses than after a single booster dose. CONCLUSION: The high amount of 7E10‐specific antibodies in patients suggests this epitope might be functionally relevant in protection. The overall characteristics of epitope‐specific antibodies are influenced by infection or vaccination background, by the used detoxification method of PT and by the amount of the toxin used in immunisation.
format Online
Article
Text
id pubmed-7396262
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73962622020-08-05 Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations Knuutila, Aapo Dalby, Tine Barkoff, Alex‐Mikael Jørgensen, Charlotte Sværke Fuursted, Kurt Mertsola, Jussi Markey, Kevin He, Qiushui Clin Transl Immunology Original Article OBJECTIVES: Pertussis toxin (PT) is a component of all acellular pertussis vaccines. PT must be detoxified to be included in acellular vaccines, which results in conformational changes in the functional epitopes of PTs. Therefore, induced epitope‐specific antibodies to PT may vary after vaccinations or natural infections, and this information could reveal biomarkers implicated for protection and successful immunisation. METHODS: Pertussis toxin epitope‐specific antibodies in sera from 152 vaccinated children and 72 serologically confirmed patients were tested with a blocking ELISA, based on monoclonal antibodies that target protective PT epitopes. RESULTS: All study groups induced considerable antibody titres to subunit 1 (S1). Of interest, S3 7E10‐specific antibodies were present in patients, but not after vaccinations (P < 0.001). The impact of glutaraldehyde treatment of PT was visible on epitope 1D7 (S1), whereas epitopes 1B7 (S1) and 10D (S1) were more preserved. Antibodies to these epitopes were higher after three primary vaccine doses than after a single booster dose. CONCLUSION: The high amount of 7E10‐specific antibodies in patients suggests this epitope might be functionally relevant in protection. The overall characteristics of epitope‐specific antibodies are influenced by infection or vaccination background, by the used detoxification method of PT and by the amount of the toxin used in immunisation. John Wiley and Sons Inc. 2020-08-02 /pmc/articles/PMC7396262/ /pubmed/32765879 http://dx.doi.org/10.1002/cti2.1161 Text en © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Article
Knuutila, Aapo
Dalby, Tine
Barkoff, Alex‐Mikael
Jørgensen, Charlotte Sværke
Fuursted, Kurt
Mertsola, Jussi
Markey, Kevin
He, Qiushui
Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations
title Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations
title_full Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations
title_fullStr Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations
title_full_unstemmed Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations
title_short Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations
title_sort differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396262/
https://www.ncbi.nlm.nih.gov/pubmed/32765879
http://dx.doi.org/10.1002/cti2.1161
work_keys_str_mv AT knuutilaaapo differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations
AT dalbytine differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations
AT barkoffalexmikael differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations
AT jørgensencharlottesværke differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations
AT fuurstedkurt differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations
AT mertsolajussi differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations
AT markeykevin differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations
AT heqiushui differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations